Creative Biolabs Launches a Full-Scale Glial Progenitor Cell (GPC) Neural Differentiation Service

Creative Biolabs now offers full assistance for neural differentiation of glial progenitors and further enhances their significant role in the field of neuroscience ex vivo models.

New York, USA – August 23, 2022 – In recent times, it has become increasingly obvious that many neurodegenerative and psychiatric disorders are causally linked to glial dysfunction. As a promising in vitro model for studying the pathology of CNS disorders, GPCs can be used to identify novel drug targets and develop therapeutic drugs. As such, Creative Biolabs launched a full-scale neural differentiation service, including but not limited to the astrocyte differentiation service, the microglia differentiation service, and the oligodendrocyte differentiation service.

* Astrocyte Differentiation

Astrocytes play a crucial role in brain development and function. Compared to neurons, astrocyte differentiation happens later in the development of nervous tissue. Hence, it takes more time as well as effective techniques to obtain pure and mature astrocytes in vitro. Depending on a rapid and reliable platform, Creative Biolabs can differentiate highly-pure populations of astrocytes with defined status, in addition to phenotypic properties from stem cells via a neural progenitor cell (NPC) intermediary. Additionally, it is feasible to provide an excellent model system for future studies of blood-brain barrier development based on an understanding of pathomechanisms, as well as drug screening and testing, due to Creative Biolabs’ successful ability to purify and culture astrocytes.

* Microglia Differentiation

Microglia contribute to various neurological disorders, such as multiple sclerosis, Parkinson’s disease, and HIV dementia, but difficulties in procuring human microglia have limited researchers’ studies. Pluripotent stem cells are widely applied in directed differentiation across astrocytes, microglia, and neuronal subtypes of the CNS. Thus, opening up new avenues for disease modeling in recent years. As a leading provider of microglia differentiation services, Creative Biolabs provides tailored STEMOD™ ex vivo model services and offers reproducible as well as scalable differentiation protocols to create further functional studies to meet the needed requirements.

* Oligodendrocyte Differentiation

A recent study indicated that the lack of myelin leads to a number of neuropsychiatric disorders and neurodegenerative diseases, such as multiple sclerosis (MS) and Huntington’s disease. Therefore, the study of oligodendrocytes and their differentiation mechanisms are essential for the development of novel therapies. With standard treatments for MS being ineffectual, stem cell replacement therapy provides an additional path toward other hopeful solutions. Also, scientists at Creative Biolabs have developed a new method for obtaining 3D neural spheroids from human-induced pluripotent stem (hiPS) cells to model oligodendrocyte development, which can further improve the understanding of mechanisms underlying oligodendrocyte differentiation regulation. As a well-recognized expert in applying advanced platforms to a broad range of neuroscience research, Creative Biolabs now provides a novel oligodendrocyte differentiation service for their global clients.

To learn more about the neural differentiation services for glial progenitors, please visit

About Creative Biolabs

Taking advantage of the advanced platform offered by the diverse STEMOD™ ex vivo model, Creative Biolabs provides comprehensive custom services for neural differentiation from glial progenitors to effectively support clients’ neuroscience research.

Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-830-6441
Country: United States